StockNews.com initiated coverage on shares of DaVita (NYSE:DVA – Get Rating) in a report issued on Thursday. The firm issued a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. Cowen boosted their target price on shares of DaVita from $76.00 to $90.00 and gave the company an outperform rating in a report on Thursday, February 23rd. Truist Financial boosted their target price on shares of DaVita from $84.00 to $90.00 and gave the company a hold rating in a report on Thursday, February 23rd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of DaVita from $72.00 to $85.00 in a report on Thursday, February 23rd. Finally, Sanford C. Bernstein initiated coverage on shares of DaVita in a report on Tuesday, March 7th. They set a market perform rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $86.43.

DaVita Stock Performance

NYSE:DVA opened at $76.77 on Thursday. The stock has a market cap of $6.94 billion, a P/E ratio of 13.28, a price-to-earnings-growth ratio of 1.56 and a beta of 0.95. The firm's fifty day simple moving average is $80.83 and its 200 day simple moving average is $80.52. DaVita has a twelve month low of $65.28 and a twelve month high of $124.81. The company has a quick ratio of 1.16, a current ratio of 1.20 and a debt-to-equity ratio of 9.92.

DaVita (NYSE:DVA – Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.23. DaVita had a net margin of 4.83% and a return on equity of 74.02%. The business had revenue of $2.92 billion for the quarter, compared to analysts' expectations of $2.93 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. The firm's revenue for the quarter was down .9% compared to the same quarter last year. As a group, research analysts predict that DaVita will post 5.93 EPS for the current year.

Insider Buying and Selling

In other DaVita news, Director Charles Berg sold 735 shares of the business's stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $81.78, for a total value of $60,108.30. Following the completion of the transaction, the director now owns 17,164 shares of the company's stock, valued at approximately $1,403,671.92. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently bought and sold shares of the business. Captrust Financial Advisors raised its position in DaVita by 3.7% in the 1st quarter. Captrust Financial Advisors now owns 3,860 shares of the company's stock worth $437,000 after buying an additional 139 shares during the last quarter. GHP Investment Advisors Inc. increased its position in shares of DaVita by 0.3% during the 2nd quarter. GHP Investment Advisors Inc. now owns 46,865 shares of the company's stock valued at $3,747,000 after purchasing an additional 144 shares during the last quarter. Sentry Investment Management LLC increased its position in shares of DaVita by 63.4% during the 4th quarter. Sentry Investment Management LLC now owns 371 shares of the company's stock valued at $28,000 after purchasing an additional 144 shares during the last quarter. Parkside Financial Bank & Trust increased its position in shares of DaVita by 88.6% during the 1st quarter. Parkside Financial Bank & Trust now owns 313 shares of the company's stock valued at $35,000 after purchasing an additional 147 shares during the last quarter. Finally, Wetherby Asset Management Inc. increased its position in shares of DaVita by 8.1% during the 1st quarter. Wetherby Asset Management Inc. now owns 2,050 shares of the company's stock valued at $232,000 after purchasing an additional 154 shares during the last quarter. Hedge funds and other institutional investors own 86.52% of the company's stock.

DaVita Company Profile

(Get Rating)

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

Featured Stories

• Get a free copy of the StockNews.com research report on DaVita (DVA)
• MarketBeat Week in Review – 3/13 – 3/17
• This Small Tech With Big Growth Prospects Is Nearing A Buy Point
• Don't Chase FedEx Higher, Wait For The Pullback
• 3 Stocks For A Defensive Tech Portfolio
• Milk the Dividends on These 3 Cash Cows

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.